News
Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.
Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...
In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...
But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that contribute to dementia risk, including obesity, type 2 diabetes ...
Top Videos American researchers found that semaglutide - the active ingredient in Ozempic and another weight loss medication, Wegovy - may lower the risk of dementia in people with type 2 diabetes.
News Ozempic ingredient linked to reduced dementia risk in diabetes patients, CWRU study shows Published: Jul. 15, 2025, 10:23 a.m.
Read more Ozempic found to slash risk of disease affecting 6.7m Americans Semaglutide and tirzepatide ¿ the powerful ingredients behind Wegovy, Ozempic and Mounjaro ¿ have long been hailed a ...
Some popular weight loss drugs — such as Ozempic, Mounjaro and Wegovy — may lower the risk of dementia and stroke for patients with Type 2 diabetes and obesity, new research suggests.
Weight loss drug Ozempic may also reduce the risk of dementia, suggests a new study. American researchers found that semaglutide - the active ingredient in Ozempic and another weight loss ...
Weight loss drug Ozempic may also reduce the risk of dementia, suggests a new study. Originally published on talker.news, part of the BLOX Digital Content Exchange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results